Your browser is no longer supported. Please, upgrade your browser.
MDVN Medivation, Inc. daily Stock Chart
Medivation, Inc.
Index- P/E- EPS (ttm)-1.17 Insider Own1.10% Shs Outstand166.00M Perf Week19.64%
Market Cap13.34B Forward P/E36.86 EPS next Y2.18 Insider Trans-1.27% Shs Float163.77M Perf Month28.58%
Income-177.10M PEG- EPS next Q0.38 Inst Own91.10% Short Float1.78% Perf Quarter32.53%
Sales1.03B P/S12.99 EPS this Y-11.10% Inst Trans-1.17% Short Ratio0.90 Perf Half Y124.63%
Book/sh3.24 P/B24.80 EPS next Y70.98% ROA-13.00% Target Price67.00 Perf Year74.54%
Cash/sh1.97 P/C40.76 EPS next 5Y37.68% ROE-23.80% 52W Range26.41 - 80.67 Perf YTD66.22%
Dividend- P/FCF43.83 EPS past 5Y50.90% ROI27.10% 52W High-0.40% Beta0.61
Dividend %- Quick Ratio4.30 Sales past 5Y72.10% Gross Margin- 52W Low204.24% ATR1.57
Employees628 Current Ratio4.30 Sales Q/Q17.40% Oper. Margin-26.30% RSI (14)90.46 Volatility0.24% 1.49%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin-17.20% Rel Volume2.33 Prev Close80.24
ShortableYes LT Debt/Eq0.00 EarningsAug 09 AMC Payout- Avg Volume3.24M Price80.35
Recom2.10 SMA2018.38% SMA5026.12% SMA20061.85% Volume7,540,951 Change0.14%
Aug-23-16Downgrade Stifel Buy → Hold
Aug-23-16Downgrade Maxim Group Buy → Hold $76 → $81.50
Aug-23-16Downgrade Credit Suisse Outperform → Neutral
Aug-22-16Downgrade SunTrust Buy → Neutral
Aug-22-16Downgrade Citigroup Buy → Neutral
Aug-10-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-12-16Reiterated Wedbush Outperform $63 → $66
May-06-16Upgrade Citigroup Neutral → Buy
May-06-16Reiterated Barclays Overweight $48 → $70
May-05-16Reiterated Maxim Group Buy $47 → $76
May-02-16Reiterated Stifel Buy $52 → $66
May-02-16Reiterated Jefferies Hold $39 → $52
Apr-29-16Reiterated Wedbush Outperform $47 → $59
Apr-06-16Initiated Sun Trust Rbsn Humphrey Buy $56
Mar-31-16Reiterated Credit Suisse Outperform $48 → $49
Mar-30-16Initiated Goldman Neutral
Feb-19-16Initiated BofA/Merrill Buy
Feb-01-16Reiterated Wedbush Outperform $59 → $47
Jan-27-16Downgrade Canaccord Genuity Buy → Hold $90 → $45
Jan-21-16Initiated Credit Suisse Outperform
Aug-27-16 12:50AM  Huge Jumps In Hedge Fund Popularity For These 5 Healthcare Stocks at Insider Monkey
12:01AM  [$$] U.K. Diners Are Nuts for Online Takeout at
Aug-26-16 10:05AM  What Should We Expect from BioMarins Kuvan in 2016?
09:24AM  Dow 30 Stock Roundup: Pfizer's Big Buy, Boeing's Big Win
09:20AM  3 Top Stocks For Retirees at Motley Fool
08:02AM  Game On for Pfizer With $14 Billion Medivation Buyout (or, Why Pfizer's Buyout of Medivation Could Be a Smart Move) at Motley Fool
Aug-25-16 10:00PM  INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Shareholders To Contact The Firm For Additional Information Business Wire
03:18PM  Pfizer (PFE) Stock Earnings Estimates Raised at Jefferies on $14 Billion Medivation Deal
02:50PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale of Medivation, Inc. for $81.50 Per Share is Fair to Shareholders Business Wire
08:31AM  How Mylan And Pfizer Could Cause A Major Biotech Backlash at Forbes
Aug-24-16 04:50PM  Biotech Stocks Seesaw As M&A Hopes Meet New Pricing Fears
03:41PM  Dear Pfizer, Stop Overpaying for Acquisitions! at Motley Fool
02:42PM  Pfizer's $1.5 Billion Antibiotics Buy: Strategic Long-Term Planning Or Pre-Split Prep?
02:09PM  Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
11:17AM  [$$] Smaller Biotech Buyout Targets After Medivation at
11:04AM  Medivation: The Latest Analyst Recommendations
10:56AM  Risk Arbitrage Trading Strategies
10:00AM  Write A Prescription For More Pharma M&A With This ETF
09:04AM  How Xtandi Fueled Big Pharmaceutical Interest in Medivation
09:04AM  Why Pfizer's Latest Deal Could Send Its Shares Soaring
08:00AM  Forget About That Pfizer Mega-Merger at Bloomberg
Aug-23-16 08:43PM  SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Medivation, Inc. -MDVN PR Newswire
03:29PM  INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale of Medivation, Inc. to Pfizer Inc. is Fair to Shareholders Business Wire
02:39PM  Pfizer & Medivation: A Big Win Like Gilead-Pharmasset or a Big Bust Like Bristol-Inhibitex? at
10:10AM  Stock Market News for August 23, 2016
09:44AM  4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss at
09:30AM  Deals of the Day: Apple Gets a Gliimpse, Pfizer's Steep Price at The Wall Street Journal
09:04AM  Pfizers Medivation Acquisition: What You Need to Know
08:58AM  Pfizer Has Had A Busy M&A Year...Or Has It?
08:47AM  Medivation (MDVN) Stock Downgraded After Pfizer Deal
07:01AM  What Pfizer Gets in Its $14 Billion Medivation Deal at Motley Fool
06:51AM  Medivation downgraded by Credit Suisse, Stifel and Maxim Group
04:50AM  Pfizer to Buy Medivation for $14B, Boost Cancer Franchise (revised)
02:52AM  Pfizer acquires biotech firm Medivation for $14 billion
12:23AM  PRESS DIGEST- New York Times business news - Aug 23
12:09AM  [$$] Pfizer to Buy Medivation for $14 Billion at The Wall Street Journal
12:07AM  [$$] Medivation Ovation: Pfizer Pays the Price for Growth at The Wall Street Journal
Aug-22-16 11:36PM  M&A is key to Pfizer's sales growth: Strategist +19.74%
11:05PM  The $150 million winner and the losers in Pfizer's $14 billion takeout of Medivation at
08:56PM  [$$] Pfizer Adds Key Cancer Drug With $14 Billion Medivation Deal at The Wall Street Journal
08:04PM  PRESS DIGEST- British Business - August 23 Reuters
07:19PM  Pfizer-Medivation cash deal is hard to justify: Analyst
07:02PM  Cramer: Forget biotech! THIS is the next red-hot takeover group at CNBC
07:01PM  Cramer: A Bunch of Semis Are Ripe for the Picking
06:54PM  Stocks Calm As Crude Plunges; Busy Day For Medical Sector
06:51PM  Pfizer Acquires Medivation
06:39PM  Pfizer boosts cancer drug roster with $14 billion Medivation deal Reuters
05:50PM  SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Investors To Contact The Firm For Additional Information Business Wire
05:32PM  In possible $14 billion ending, Medivation goes back to early days at
05:25PM  Biotech's next big deal?
05:06PM  Pfizer (PFE) Bought Medivation (MDVN), but is it a Good Deal?
05:04PM  What Happened in the Stock Market Today at Motley Fool
04:43PM  U.S. Stocks Ease as Markets Watch Oil, Fed at The Wall Street Journal
04:31PM  Stocks End Little-Changed; Zoe's Kitchen Plunges After Hours
04:31PM  Medivation shares leap on Pfizer's $14 billion offer at CNBC
04:29PM  Pfizer-Medivation Deal Reignites Biotech Buyout Speculation
04:27PM  Pfizer's Medivation buy seen prescribing more biotech M&A Reuters
04:27PM  Pfizer-Medivation Deal Headlines Busy Merger Monday
04:21PM  Market Keeps Chasing Its Own Tail
04:10PM  Here's a Reason Why Tesaro (TSRO) Stock Climbed Today
04:05PM  Valeant Stock Jumps On CFO Appointment, As M&A Hopes Rise
04:02PM  Stocks Waver as Investors Wait for Fed Clarity
02:57PM  After Medivation, These 6 Biotech Stocks Could Be M&A Targets Next at
02:47PM  Stocks Struggle for Direction as Jackson Hole Conference Looms
02:43PM  Betting on BioMarin at Bloomberg
02:35PM  Bernie Sanders Just Called Out Pfizer and Medivation on Twitter
02:20PM  Pfizer Acquires Medivation, Renews Biotech M&A Bets
02:08PM  Medivation, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with Pfizer Inc. Business Wire
02:05PM  Medivation Scores Premium in Sale to Pfizer
01:52PM  Stocks Struggle For Direction As Oil Sinks, Biotechs Soar
01:24PM  [$$] Pfizer makes $14bn bet on cancer drugmaker Medivation at Financial Times
01:23PM  [$$] Pfizer/Medivation: combination therapy at Financial Times
01:14PM  Biotechs Rise on Bet Medivation Losers Will Look to Next Deal
01:08PM  Pfizer to buy Medivation
12:52PM  [$$] Medivation Ovation: Pfizer Pays the Price for Growth at The Wall Street Journal
12:46PM  Medivation shareholders should be thrilled about price of Pfizer deal: analysts at MarketWatch
12:36PM  Monday links: work and drudgery
12:33PM  Pfizer Claims Pharmaceutical's Latest Big Prize
12:20PM  Medivation's Shares Have Tripled Since February at The Wall Street Journal
12:07PM  Incyte (INCY) Stock Rises on Takeover Speculation After $14 Billion Pfizer, Medivation Deal
12:01PM  ETFs in Focus on Pfizer's Medivation Acquisition
11:57AM  Biotech stocks rally as investors bet on the next big tie-up at CNBC
11:46AM  Pfizer spends $14B on Medivation in cancer fight
11:21AM  Stocks Retreat As Planet Fitness Rises Near High
11:16AM  Medivation's Shares Soar on Confirmation of a Pfizer Buyout at Motley Fool
11:04AM  The Word on the Street: How Do Analysts See Horizon Pharma?
10:56AM  MEDIVATION, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Business Wire
10:50AM  Upstart banks just yanked another big deal away from Wall Street at CNBC
10:39AM  Understanding Medivations Premium Valuation
10:28AM  Pfizer spent $14 billion on a company with just one approved drug here's why that's a game-changer
10:26AM  More Squawk from Jim Cramer: Pfizer Buys Medivation (MDVN) for $14 Billion
10:21AM  Nasdaq Turns Up; Medivation, Syngenta, Intersil Soar On Merger News
10:20AM  Pfizer Won the Bidding War for Medivation But Is It Really a Win? at
10:06AM  Pfizer buys Medivation $14 billion cash
09:53AM  Pfizer Will Buy Cancer Drugmaker Medivation For $14 Billion
09:45AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Medivation, Inc. to Pfizer Inc. is Fair to Shareholders -- MDVN Accesswire
09:20AM  Deals of the Day: Pfizer Nabs Medivation, Syngenta Deal Gets U.S. Approval at The Wall Street Journal
09:16AM  Why Pfizer, Medivation, GM, and 2 Other Stocks Have Investors Talking at Insider Monkey
09:09AM  Pfizer boosts cancer drug pipeline with $14 bln Medivation deal
08:40AM  MEDIVATION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of S
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of medical therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (CRPC) patients. The company also develops Enzalutamide, which is in phase III clinical trials for the treatment of non-metastatic CRPC, and metastatic and non-metastatic hormone sensitive prostate cancer; and phase II clinical trials for the treatment of hepatocellular carcinoma, androgen receptor positive (AR+) triple negative breast cancer, estrogen receptor positive or progesterone receptor positive and human epidermal growth factor receptor 2 (HER2) normal breast cancer, and AR+ HER2 amplified breast cancer. In addition, it develops Talazoparib, which is in phase II clinical trials for treatment of germline mutated HER2 normal breast cancer; Pidilizumab that is in phase II clinical trials for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and MDV4463, which is in phase I clinical trials for the treatment of nonalcoholic steatohepatitis. The company has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI; and License and Manufacturing and supply agreement with CureTech, Ltd. for the development, manufacture, and commercialization of biologic molecules. Medivation, Inc. is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Powell Andrew Kenneth WilliamSVP, General Counsel & Crp SecJun 06Sale60.422,578155,76328,517Jun 06 08:10 PM
Bierly RickCFO (former)May 06Sale60.126,315379,63728,744May 09 05:35 PM
Bierly RickCFO (former)May 05Sale59.204,025238,28035,059May 09 05:35 PM
Svoronos DawnDirectorMar 14Sale38.906,000233,40018,234Mar 16 05:06 PM
Hirmand MohammadInterim Chief Medical OfficerMar 04Sale41.101,52562,68539,342Mar 07 08:44 PM
Bierly RickChief Financial OfficerMar 04Sale40.002,998119,92039,084Mar 07 08:43 PM
Hung DavidPresident and CEOFeb 04Sale31.186,350197,9931,504,654Feb 05 07:05 PM
Machado Clarence PatrickDirectorJan 19Option Exercise3.3775,000252,525141,156Jan 21 05:45 PM
Machado Clarence PatrickDirectorJan 19Sale37.3475,0002,800,56266,156Jan 21 05:45 PM
Lobacki Joseph MChief Commercial OfficerJan 04Sale46.503,065142,52319,365Jan 05 06:14 PM
VERNON W ANTHONYDirectorDec 14Buy40.6915,000610,35028,704Dec 16 05:40 PM
Hung DavidPresident and CEODec 03Sale43.1010,950471,9661,511,004Dec 04 04:36 PM
Hirmand MohammadInterim Chief Medical OfficerDec 03Sale43.401,07546,65531,113Dec 04 04:35 PM
Hirmand MohammadInterim Chief Medical OfficerNov 09Sale41.912329,72232,188Nov 12 06:46 PM
Svoronos DawnDirectorSep 08Sale89.153,100276,36512,117Sep 08 07:39 PM